<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144092</url>
  </required_header>
  <id_info>
    <org_study_id>147</org_study_id>
    <secondary_id>15841</secondary_id>
    <nct_id>NCT00144092</nct_id>
  </id_info>
  <brief_title>HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma</brief_title>
  <official_title>High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem
      cell transplanation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem
      cell transplanation if they have an HLA matched sibling, or an autologous transplant if they
      do not.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>event free survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Low Grade Lymphoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cell source</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indolent histology lymphomas after relapse 1 or 2 LVEF &gt; 50% Creatinine &lt; 150 umol/L
             bilirubin &lt; 30 umol/L wbc &gt;3.5X10^9/L platelets &gt;100X10^9/L other medical condition as
             controlled

        Exclusion Criteria:

          -  pregnant lactating HIV positive CNS involvement by lymphoma other malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Stewart</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alberta Cancer Board - TBCC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>November 18, 2011</last_update_submitted>
  <last_update_submitted_qc>November 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2011</last_update_posted>
  <keyword>autologous and allogeneic stem cell transplantation</keyword>
  <keyword>low grade lymphoma</keyword>
  <keyword>mantle cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

